Insider filing · TCRX

Lynx1 Capital Management LP bought $3.1M of TScan Therapeutics (TCRX)

Executed May 19 2025, disclosed May 21 2025, 2 days later.

Over the 21 trading sessions from the disclosed entry session (May 21 2025), the stock returned +17.1% (delay-adjusted); from the execution session (May 19 2025), +27.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

LL Lynx1 Capital Management LP 10% owner profile →

Lynx1 Capital Management LP (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Passage Bio, Inc. (PASG). Across 1 priced purchase filing, the average 21-session return was +1.5% from execution and -0.7% from disclosure (delay-adjusted; derived). The largest single filing was $854K of KRRO (77,299 sh across 3 lots, as filed), executed Oct 22.

TCRX TCRX TCRX · 2 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→